AI-VISION Study Launched to Improve Precision Therapy in Breast Cancer

Researchers from ICR, the Royal Marsden, and experts from the University of Durham and Concr are launching an AI-based clinical study to improve precision therapy in breast cancer. The AI-VISION study will profile tissue samples from patients with triple-negative breast cancer to define and validate biomarkers of chemotherapy response. This two-year study, funded by Innovate UK, aims to deliver precision medicine and improve clinical decision-making for cancer patients.